# A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

> **NCT01789242** · PHASE1 · COMPLETED · sponsor: **Criterium, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Amyloidosis
- Systemic Light Chain Amyloidosis

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01789242
- **Lead sponsor:** Criterium, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2016-12
- **Final completion:** 2017-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01789242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01789242, "A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01789242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*